Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerPolicy UpdatesRadiation OncologyUniversity of Utah Proton Beam Coverage | OpenPaye…
    Ask Trek AI about this page
    ModifiedUniversity of Utah Health PlansPolicy MP-009

    Proton Beam Therapy

    Customize your policy alerts

    Sign up for universityofutahhealthplans Policy MP-009 alerts

    Get alerted when Policy MP-009 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of proton beam therapy for University of Utah Health Plans commercial, CHIP, and Medicaid members. It establishes diagnosis- and age-based medical necessity criteria, with Medicaid coverage generally determined by Utah Medicaid or applicable InterQual criteria.

    Policy Summary
    PayerUniversity of Utah Health Plans
    PolicyProton Beam Therapy
    Policy CodePolicy MP-009
    Change TypeModified
    Effective DateOctober 25, 2026
    Last ReviewSep 25, 2026
    Next Review DateSeptember 1, 2027
    Key ActionObtain prior authorization before providing proton beam therapy when the service is subject to prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    Coverage criteria added adult indications such as chordomas and chondrosarcomas, vestibular schwannoma, uveal melanoma, arteriovenous malformations, selected head and neck cancers, sinonasal and nasopharyngeal cancers, prostate cancer, and liver cancers.

    Coverage criteria added pediatric malignancies and other primary brain and spinal tumors adjacent to critical structures that cannot be adequately spared using photon-based radiation therapy techniques.

    11Adult diagnosis categories listed as potentially covered

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    18 years
    Adult age threshold
    <18 yearsPediatric age criterion
    Prior authorizationCoverage requirement

    Medical Necessity and Coverage Criteria

    Commercial Plans/CHIP covered indications

    For Commercial Plans and CHIP, proton beam therapy is covered when the applicable age pathway and diagnosis criteria are met.

    Applicable age pathway

    • Adult pathway

      • Adult age: Member is age 18 years or older.>=18 years

      • Adult diagnosis

        • Listed adult diagnoses: Benign or malignant meningioma; pituitary adenoma; vestibular schwannoma (acoustic neuroma); chordoma or chondrosarcoma of the skull base or spine; intraocular (uveal) melanoma; arteriovenous malformation (AVM); locally advanced or unresectable head and neck cancer; paranasal sinus, maxillary sinus, ethmoid sinus, nasal cavity, or nasopharyngeal cancer; intermediate-risk, unfavorable intermediate-risk, high-risk, or very high-risk prostate cancer; liver hepatocellular carcinoma or intrahepatic bile duct cancer; or another primary brain or spinal tumor adjacent to critical structures, including the optic nerves, optic chiasm, brainstem, or spinal cord, that cannot be sufficiently spared using photon-based radiation therapy techniques.One of 11 listed categories

    • Pediatric pathway

      • Pediatric age: Member is under age 18 years.<18 years
      • Pediatric diagnosis: Member has a malignancy.Malignancy

    Medicaid coverage pathway

    For Medicaid members, coverage is determined under the State of Utah Medicaid program.

    • Utah Medicaid position: Apply the Utah State Medicaid published coverage position.Published Utah Medicaid coverage position

      Consult Utah Medicaid official publications or the Utah Medicaid code Look-Up tool.

    • InterQual pathway: Apply InterQual criteria when available.Available InterQual criteria
    • Fallback Commercial criteria: If Utah Medicaid has no published coverage position and InterQual criteria are unavailable, apply the U of U Health Plans Commercial criteria.No Utah Medicaid position and no InterQual criteria

    Dosimetric medical-appropriateness framework

    ASTRO considers proton beam therapy medically appropriate when its dosimetric properties provide a clinically meaningful reduction in radiation exposure to surrounding normal tissues and critical structures.

    Clinical rationale supporting proton therapy

    • Reduced normal-tissue dose is expected to decrease the risk of clinically significant toxicity.
    • Target adjacent to critical organs: The treatment target is adjacent to critical organs or structures where dose reduction is clinically important.
    • Reirradiation is required and proton therapy may reduce dose to previously irradiated tissues.

    Disease sites frequently supporting proton therapy

    Disease sites identified by ASTRO as frequently supporting use of proton beam therapy include the following; treatment selection should be individualized and supported by documentation of the expected dosimetric benefit.

    Disease-site considerations

    • Pediatric malignancies: Pediatric malignancy.
    • CNS, skull-base, or craniospinal tumors: Primary or benign central nervous system tumor; skull-base chordoma or chondrosarcoma; or tumor requiring craniospinal irradiation.
    • Ocular tumors: Ocular tumor, including uveal or choroidal melanoma.
    • Head and neck cancers: Advanced head and neck cancer, nasopharyngeal cancer, or sinonasal cancer.

    Covered Procedure Codes

    CPT CodesCPT
    77520Proton treatment delivery; simple, without compensation
    77522Proton treatment delivery; simple, with compensation
    77523Proton treatment delivery; intermediate
    77525Proton treatment delivery; complex

    Authorization and Documentation Requirements

    Prior Authorization

    Obtain prior authorization

    Obtain prior authorization before providing proton beam therapy when the service is subject to prior authorization.

    Documentation Required

    Document expected dosimetric benefit

    Document that proton therapy is expected to provide a meaningful reduction in radiation dose to normal tissues compared with available photon-based techniques. The documentation should support the individualized treatment selection.

    Denial Risk

    Proton Beam Therapy Overview

    Proton beam therapy (PBT) is an external-beam radiation treatment that uses positively charged protons to deliver radiation to a targeted treatment area. Unlike conventional photon-based radiation therapy, protons deposit most of their dose at a specified tissue depth, known as the Bragg Peak, followed by a rapid dose falloff beyond the target. This physical property allows highly conformal radiation delivery while potentially reducing exposure to adjacent healthy tissues and critical structures, including the brain, brainstem, spinal cord, optic pathways, salivary glands, heart, and lungs.

    Key Terms

    Bragg Peak
    TermBragg Peak
    Dose depositionThe specific depth within tissue where proton therapy deposits the majority of its radiation dose.
    Dose beyond targetRadiation dose falls off rapidly beyond the targeted area.
    Proton Beam Therapy
    ModalityExternal beam radiation therapy.
    Radiation sourceUses positively charged particles called protons.
    Treatment purposeDelivers radiation to a targeted treatment area.
    Policy Summary
    PayerUniversity of Utah Health Plans
    PolicyProton Beam Therapy
    Policy CodePolicy MP-009
    Change TypeModified
    Effective DateOctober 25, 2026
    Last ReviewSep 25, 2026
    Next Review DateSeptember 1, 2027
    Key ActionObtain prior authorization before providing proton beam therapy when the service is subject to prior authorization.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaCovered Procedure CodesAuthorization and Documentation RequirementsProton Beam Therapy OverviewKey Terms

    A CPT or HCPCS code covered by Utah Medicaid may still require further evaluation to determine medical necessity.

  1. Liver cancers: Hepatocellular carcinoma or intrahepatic biliary cancer.
  2. Selected reirradiation case.

    3. Missing prior authorization may affect coverage

    Services requiring prior authorization may not be covered when prior authorization is not obtained.

    Note

    Confirm Medicaid coverage criteria

    For Medicaid members, follow the State of Utah Medicaid coverage position. If Utah Medicaid has no published coverage position and InterQual criteria are unavailable, apply the U of U Health Plans Commercial criteria; a Utah Medicaid-covered CPT or HCPCS code may still require further medical-necessity evaluation.